Epidermal growth factor receptor mutations in lung adenocarcinoma.
about
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachLigand-Independent EGFR SignalingEpidermal growth factor receptor in non-small cell lung cancerTERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung CancerIn vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patientsComparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.The LRIG family: enigmatic regulators of growth factor receptor signaling.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerModels: stretching the skills of cell lines and mice.Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective studyThe EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.Differential Regulation of Gene Expression of Alveolar Epithelial Cell Markers in Human Lung Adenocarcinoma-Derived A549 Clones.Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing.Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsExosomal miRs in Lung Cancer: A Mathematical Model.Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.High expression of cellular retinol binding protein-1 in lung adenocarcinoma is associated with poor prognosis.Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of ChinaThe Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor MutationNF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung CancerBaseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancerPredictive radiogenomics modeling of EGFR mutation status in lung cancerRole of epidermal growth factor receptor in lung cancer and targeted therapies.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerRadiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.Identification and Validation of Driver Kinases from Next-Generation Sequencing Data.Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.Investigational new drugs for brain cancer.TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.EGFR mutations in non-small cell lung cancer: an audit from West China Hospital.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
P2860
Q24672143-B45624BD-D42B-4074-B4B8-AFF2043E5277Q26797495-4ED5E719-22AA-40AF-9477-31E7EF9B99F2Q28088636-C9470681-AB90-4973-9897-A66AE1FDBFBCQ28393844-70D28D53-0742-45F2-9249-3D19414874E1Q30372076-BB1CC7E9-B073-4F08-A952-93FD9A5E4A5AQ33702017-2018E624-EB38-4826-A3EC-E8CA88E9663CQ33881082-56B3CCEB-14CD-4AE7-B5DC-41DBFDEF5816Q34276176-A945E73F-159A-4978-8650-3252FE118F40Q34295621-38DCBAFA-F5B5-4931-BE90-A092D4D26862Q34421927-ABEEDF37-11D2-40EA-9A6D-AB7283271035Q35001781-85EBADD6-51C7-492A-A665-F374F016631EQ35556136-4F76A8AF-DC66-44D4-9ABB-D68715E2DC17Q35725518-1D8AF187-0A46-480E-9FD3-099C0537BC10Q35807277-B993200D-A037-44AB-B4BC-7400113C3443Q35811159-EF42A25D-CF9C-456D-92CA-FCE9141E1789Q35842446-DED5B62A-293F-4998-8A44-666EB4F4EE95Q36088722-65844E86-27C4-4C89-99FA-DE43F49E0032Q36116376-F242BF81-80A0-49B1-9529-977A63A241A5Q36230579-2579203D-B6E6-4B0E-9B8D-95DE7E693D8FQ36304631-46168546-B7FD-4FC3-8026-B35033A8433CQ36430129-10BDB0FF-E23F-49C1-B77B-822AF1843CF0Q36825159-94516AF7-DB78-4052-9784-7D2A54072CB8Q36939336-CBBACC3F-563B-4E64-8761-9AA878C98E13Q37173070-6D137819-8963-487B-BE75-0170314287A9Q37339704-85639A0C-A371-45CE-9A4F-1D3494DB4E8AQ37479765-825BAC94-FCCE-4F97-BFED-1846E3FF4EDBQ37615306-49769879-AC7C-4071-8CE6-415B8BA83AAEQ37679981-64324E82-BDFA-43F4-8B60-CC3C75ABA71FQ37701159-DE344246-D723-4D41-A74E-FB18289387A8Q38564088-4AD217FA-DCC4-41D2-8873-39175E153C31Q38668707-3E85AC06-5D1E-4EB8-97BE-BCC51312853BQ38750358-370CFFB9-019D-489E-B4CA-9F1F72D27DF3Q38804094-D817AA3D-1C72-4085-BFCB-D9D648C4EB11Q38832510-3FE2A974-5825-4328-ACA2-AE83749EF69EQ38888391-4DBB391D-3016-45CA-BFA5-F9538DF44A2DQ38940817-D4C37ED0-0DCE-4BCD-BEDB-3B4F828E3E1AQ39255218-35A46854-3635-4724-A5AE-7655223AE295Q39651867-89A183D8-7540-4105-9174-FCA1EB95C2BAQ40393934-DC654419-5050-4E94-BABE-6BEE6C2C88D3Q41260159-02323967-E052-4226-9964-38BAA9C1DE7E
P2860
Epidermal growth factor receptor mutations in lung adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epidermal growth factor receptor mutations in lung adenocarcinoma.
@en
type
label
Epidermal growth factor receptor mutations in lung adenocarcinoma.
@en
prefLabel
Epidermal growth factor receptor mutations in lung adenocarcinoma.
@en
P2860
P1476
Epidermal growth factor receptor mutations in lung adenocarcinoma.
@en
P2093
Alain C Borczuk
Markus D Siegelin
P2860
P2888
P304
P356
10.1038/LABINVEST.2013.147
P577
2013-12-30T00:00:00Z
P5875
P6179
1001165371